DDInter704 DDInter280
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Canagliflozin
Everolimus {u} (Compound) causes {v} (Side Effect) Hyperkalaemia
Hyperkalaemia {u} (Side Effect) is caused by {v} (Compound) Canagliflozin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} (Compound) resembles {v} (Compound) Canagliflozin
Everolimus {u} (Compound) causes {v} (Side Effect) Hyperkalaemia
Hyperkalaemia {u} (Side Effect) is caused by {v} (Compound) Perindopril
Perindopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Everolimus {u} (Compound) causes {v} (Side Effect) Dyslipidaemia
Dyslipidaemia {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Dapagliflozin {u} (Compound) resembles {v} (Compound) Canagliflozin
Everolimus {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Canagliflozin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Dapagliflozin {u} (Compound) resembles {v} (Compound) Canagliflozin
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Canagliflozin
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound)
Everolimus (Compound) causes Hyperkalaemia (Side Effect) and Hyperkalaemia (Side Effect) is caused by Canagliflozin (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Everolimus (Compound) causes Hyperkalaemia (Side Effect) and Hyperkalaemia (Side Effect) is caused by Perindopril (Compound) and Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Everolimus (Compound) causes Dyslipidaemia (Side Effect) and Dyslipidaemia (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Everolimus (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Canagliflozin
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)